In their study, Aïda Sampera et al. found that the development of drug resistance in HER2-positive GC cell lines was associated with sustained activation of the MAPK-ERK and PI3K-mTOR pathways mediated by SRC [126]. The gene discussed is ERBB2; the disease is gastric cancer.